The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients
Public ClinicalTrials.gov record NCT01163617. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Open-Label Study of the Injection Time and Usability of the Physiolis Syringe and Autoinjector in Injection-Experienced Rheumatoid Arthritis Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was an open-label, Phase 2 study designed to obtain user experience data (Phase A) and injection time data (Phase B) in experienced adalimumab patients injected with the Physiolis pre-filled syringe and autoinjector used to administer adalimumab.
Study identification
- NCT ID
- NCT01163617
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 85 participants
Conditions and interventions
Conditions
Interventions
- Adalimumab delivered in current syringe Device
- Adalimumab delivered in Physiolis syringe Device
- Adalimumab delivered in current autoinjector Device
- Adalimumab delivered in Physiolis autoinjector Device
Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2010
- Primary completion
- Oct 31, 2010
- Completion
- Oct 31, 2010
- Last update posted
- Jul 1, 2018
2010
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 27144 | Victorville | California | 92395 | — |
| Site Reference ID/Investigator# 27153 | Tampa | Florida | 33614 | — |
| Site Reference ID/Investigator# 27150 | Passaic | New Jersey | 07055 | — |
| Site Reference ID/Investigator# 27143 | Duncansville | Pennsylvania | 16635 | — |
| Site Reference ID/Investigator# 27145 | Wyomissing | Pennsylvania | 19610 | — |
| Site Reference ID/Investigator# 27142 | Charleston | South Carolina | 29406 | — |
| Site Reference ID/Investigator# 27151 | Jackson | Tennessee | 38305 | — |
| Site Reference ID/Investigator# 27152 | Dallas | Texas | 75231 | — |
| Site Reference ID/Investigator# 27147 | Houston | Texas | 77074 | — |
| Site Reference ID/Investigator# 27155 | Tyler | Texas | 75701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01163617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2018 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01163617 live on ClinicalTrials.gov.